Glenmark Pharmaceuticals is bringing to India Remogliflozin etabonate, a drug used to treat adults with Type 2 diabetes. Glenmark did the phase III clinical trials for Remogliflozin in India after it received certain rights to it through a licensing collaboration with BHV Pharma.
- It is an SGLT2 inhibitor indicated in the treatment of type-2 diabetes mellitus in adults
- SGLT2 inhibitors provide glycemic control, induce weight loss and reduce cardiovascular risks
- Glenmark is the first to launch Remogliflozin and India is the first country to get access to the innovative drug
- Other SGLT2 class of drugs include Empagliflozin, Dapagliflozin and Canagliflozin
Glenmark will commercialise Remogliflozinin India under the brand names “Remo” and “Remozen”.
Glenmark, the company’s press release points out, received regulatory approval for Remogliflozin etabonate 100 mg tablets, twice daily, after successfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin. Remogliflozin, it says, is the latest drug in SGLT2 inhibitors’class to get regulatory approval in the world, has been studied in 26 clinical trials globally, covering around 2,500 people from various ethnicities.